Adenocarcinoma of the cervix

John O. Schorge, Lynne M. Knowles, Jayanthi S. Lea

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Cervical adenocarcinomas are increasing in incidence each year, comprising up to 25% of all cervical cancers diagnosed in the United States. This increase largely reflects the inherent difficulty in detecting glandular precursor lesions using current screening practices. However, there also appears to be a recent shift in the epidemiology of the disease process with younger women being diagnosed more frequently. Fertility-sparing surgery is an option for selected patients with adenocarcinoma in situ or stage IA1 cervical adenocarcinoma. Simple hysterectomy should be performed at the completion of childbearing or when preserving fertility is not an issue. The treatment of choice for most women with stage IA2 to IB1 disease is radical hysterectomy. Fewer than 20% of patients wilt need adjuvant therapy and the cure rate is excellent. Primary radiation with weekly cisplatin may be the best option for patients with stage IB2 to IIA cervical adenocarcinoma. Patients treated initially by primary radical surgery will almost certainly require postoperative chemoradiation because of high-risk surgical-pathologic features. Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy.

Original languageEnglish (US)
Pages (from-to)119-127
Number of pages9
JournalCurrent Treatment Options in Oncology
Volume5
Issue number2
StatePublished - Apr 2004

Fingerprint

Cervix Uteri
Adenocarcinoma
Hysterectomy
Cisplatin
Fertility
Radiation
Uterine Cervical Neoplasms
Epidemiology
Therapeutics
Recurrence
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schorge, J. O., Knowles, L. M., & Lea, J. S. (2004). Adenocarcinoma of the cervix. Current Treatment Options in Oncology, 5(2), 119-127.

Adenocarcinoma of the cervix. / Schorge, John O.; Knowles, Lynne M.; Lea, Jayanthi S.

In: Current Treatment Options in Oncology, Vol. 5, No. 2, 04.2004, p. 119-127.

Research output: Contribution to journalArticle

Schorge, JO, Knowles, LM & Lea, JS 2004, 'Adenocarcinoma of the cervix', Current Treatment Options in Oncology, vol. 5, no. 2, pp. 119-127.
Schorge JO, Knowles LM, Lea JS. Adenocarcinoma of the cervix. Current Treatment Options in Oncology. 2004 Apr;5(2):119-127.
Schorge, John O. ; Knowles, Lynne M. ; Lea, Jayanthi S. / Adenocarcinoma of the cervix. In: Current Treatment Options in Oncology. 2004 ; Vol. 5, No. 2. pp. 119-127.
@article{fedbaab8fbf747fb9dc288bc50e6a169,
title = "Adenocarcinoma of the cervix",
abstract = "Cervical adenocarcinomas are increasing in incidence each year, comprising up to 25{\%} of all cervical cancers diagnosed in the United States. This increase largely reflects the inherent difficulty in detecting glandular precursor lesions using current screening practices. However, there also appears to be a recent shift in the epidemiology of the disease process with younger women being diagnosed more frequently. Fertility-sparing surgery is an option for selected patients with adenocarcinoma in situ or stage IA1 cervical adenocarcinoma. Simple hysterectomy should be performed at the completion of childbearing or when preserving fertility is not an issue. The treatment of choice for most women with stage IA2 to IB1 disease is radical hysterectomy. Fewer than 20{\%} of patients wilt need adjuvant therapy and the cure rate is excellent. Primary radiation with weekly cisplatin may be the best option for patients with stage IB2 to IIA cervical adenocarcinoma. Patients treated initially by primary radical surgery will almost certainly require postoperative chemoradiation because of high-risk surgical-pathologic features. Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy.",
author = "Schorge, {John O.} and Knowles, {Lynne M.} and Lea, {Jayanthi S.}",
year = "2004",
month = "4",
language = "English (US)",
volume = "5",
pages = "119--127",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Adenocarcinoma of the cervix

AU - Schorge, John O.

AU - Knowles, Lynne M.

AU - Lea, Jayanthi S.

PY - 2004/4

Y1 - 2004/4

N2 - Cervical adenocarcinomas are increasing in incidence each year, comprising up to 25% of all cervical cancers diagnosed in the United States. This increase largely reflects the inherent difficulty in detecting glandular precursor lesions using current screening practices. However, there also appears to be a recent shift in the epidemiology of the disease process with younger women being diagnosed more frequently. Fertility-sparing surgery is an option for selected patients with adenocarcinoma in situ or stage IA1 cervical adenocarcinoma. Simple hysterectomy should be performed at the completion of childbearing or when preserving fertility is not an issue. The treatment of choice for most women with stage IA2 to IB1 disease is radical hysterectomy. Fewer than 20% of patients wilt need adjuvant therapy and the cure rate is excellent. Primary radiation with weekly cisplatin may be the best option for patients with stage IB2 to IIA cervical adenocarcinoma. Patients treated initially by primary radical surgery will almost certainly require postoperative chemoradiation because of high-risk surgical-pathologic features. Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy.

AB - Cervical adenocarcinomas are increasing in incidence each year, comprising up to 25% of all cervical cancers diagnosed in the United States. This increase largely reflects the inherent difficulty in detecting glandular precursor lesions using current screening practices. However, there also appears to be a recent shift in the epidemiology of the disease process with younger women being diagnosed more frequently. Fertility-sparing surgery is an option for selected patients with adenocarcinoma in situ or stage IA1 cervical adenocarcinoma. Simple hysterectomy should be performed at the completion of childbearing or when preserving fertility is not an issue. The treatment of choice for most women with stage IA2 to IB1 disease is radical hysterectomy. Fewer than 20% of patients wilt need adjuvant therapy and the cure rate is excellent. Primary radiation with weekly cisplatin may be the best option for patients with stage IB2 to IIA cervical adenocarcinoma. Patients treated initially by primary radical surgery will almost certainly require postoperative chemoradiation because of high-risk surgical-pathologic features. Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy.

UR - http://www.scopus.com/inward/record.url?scp=3142710860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142710860&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 119

EP - 127

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 2

ER -